Fig 4.

HSPGs mediate attachment of filovirus to the cells. 293T, Huh7, and HUVEC cells were pretreated or mock treated with different amounts of heparinase I or heparinase III and exposed to concentrated HIV pseudotypes bearing EBOV, MARV, or Lassa virus envelope glycoproteins (A) or EBOV and Lassa virus β-lactamase-based VLPs (B). Results are expressed as percentages of results with no heparinase and represent the means ± SD for duplicate wells. Heparinase concentrations are expressed in units. The results are representative of at least three different experiments.